Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote
FDA advisory panel backed Replimune's RP1 melanoma data ahead of the agency's August 2 decision despite earlier staff criticism.
An FDA expert group said Replimune's cancer medicine looked promising, even though FDA staff had concerns before. When experts support a drug, it signals the company might get approval, which is a positive sign to watch for.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.